MRD-guided therapy for early-stage lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether monitoring for minimal residual disease (MRD) after surgery can help guide decisions about additional therapy for stage I non-small cell lung cancer (NSCLC). If you've had surgery to completely remove your cancer and are eligible, you may benefit from a personalized approach to follow-up treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-small cell lung cancer (NSCLC) and had surgery to completely remove the tumor (stage IA or IB).
- You are at least 18 years old and no older than 75.
- You have recovered from surgery and are in generally good health (able to perform daily activities).
- You have adequate organ function (bone marrow, liver, kidneys) as checked by standard blood tests.
- You have not had any prior cancer treatment for this lung cancer, including chemotherapy, radiation, or targeted therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This trial uses a blood test (ctDNA and CTC) to check for minimal residual disease (MRD) after treatment for stage IIA-IIIC non-small cell lung cancer. The goal is to see if MRD can help predict whether the cancer will come back and guide decisions on extra treatment to prevent recurrence.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests if removing the main lung tumor followed by the targeted therapy osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer. It is for those who have not had prior treatment and are healthy enough for surgery.
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.